Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9794692 | 0.98 | GLA (0.59) | GLAHSD17B10KDM4EALDH1A1POLB | |
| SCHEMBL4710666 | 0.84 | KDM4E (0.53) | GLAKDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL526447 | 0.82 | GLA (0.62) | GLAHSD17B10KDM4EALDH1A1POLB | |
| SCHEMBL6786534 | 0.81 | SMN1; SMN2 (0.57) | KDM4EALDH1A1POLBL3MBTL1MEN1 | |
| SCHEMBL12120192 | 0.81 | TDP1 (0.51) | GLAKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL111438 | 0.80 | TSHR (0.58) | GLAKDM4EALDH1A1HTR2AHTR2B | |
| SCHEMBL7608229 | 0.79 | GLA (0.48) | GLAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6691875 | 0.79 | TDP1 (0.45) | KDM4EALDH1A1L3MBTL1TDP1HTR2A | |
| SCHEMBL3830838 | 0.79 | GLA (0.49) | GLAHSD17B10KDM4EALDH1A1POLB | |
| SCHEMBL11281615 | 0.78 | KDM4E (0.50) | GLAKDM4EALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PROTEOLIX, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170075218-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170075218-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2270026-B1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2270026-A2 | Compounds for proteasome enzyme inhibition | Onyx Therapeutics, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2266999-A2 | Compounds for proteasome enzym inhibition | Onyx Therapeutics, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7417042-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417042-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2006017842-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| CN-1039248-A | The preparation method of new bisphosphate derivative | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | GLA 2224/4885HSD17B10 3931/4885KDM4E 2768/4885 |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | GLA 2091/4885HSD17B10 4280/4885KDM4E 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.